Background {#Sec1}
==========

Patients with acute respiratory failure almost always develop gas exchange derangements that may result in hypercapnia \[[@CR1]\]. Lung-protective ventilation strategies are strongly recommended to prevent additional lung injury \[[@CR2], [@CR3]\], but these strategies have a strong potential to increase plasma carbon dioxide levels further. One approach is to accept this, i.e., "permissive hypercapnia," with the option to correct respiratory acidosis by slow bicarbonate infusion for blood buffering. Extracorporeal decapneization by utilizing "extracorporeal CO~2~ removal" (ECCO~2~R) is an appealing alternative for permissive hypercapnia but comes with the typical risks of extracorporeal circulation.

Hypercapnia has been suggested to have beneficial effects, including a reduction in pulmonary inflammation and alveolar oxidative stress \[[@CR4]--[@CR7]\]. Hypercapnia, however, may also have deleterious effects, such as impairments in tissue repair and decreased alveolar fluid clearance \[[@CR8]--[@CR11]\]. Seen these seemingly opposite effects, it becomes increasingly important to determine the net consequence of hypercapnia. Indeed, the number one question in patients with acute respiratory distress syndrome (ARDS), who either have hypercapnia or develop hypercapnia as a consequence of lung-protective ventilator settings, is whether hypercapnia should be accepted, or prevented and corrected.

This narrative review provides an overview of the various biological and physiological effects of hypercapnia and discusses current strategies affecting the plasma carbon dioxide levels in ARDS patients.

Biological effects of hypercapnia---preclinical studies {#Sec2}
=======================================================

Several preclinical studies have shown hypercapnia displays profound impact on alveolar cells and humoral factors that all could play a role in lung injury. Some of these effects can be seen as potentially beneficial, while others, in theory, could be harmful.

Effects of hypercapnia on alveolar cells (Table [1](#Tab1){ref-type="table"}) {#Sec3}
-----------------------------------------------------------------------------

Hypercapnia has been found to decrease microvascular permeability, lung edema formation, and bronchoalveolar lavage protein content in the rabbit lungs subjected to ex vivo ventilation with high pressures \[[@CR4]\]. Hypercapnia also reduced histologically confirmed lung injury in ventilated mice \[[@CR5]\]. The plausible mechanisms are related to the action of carbon dioxide upon the nuclear factor kappa pathway, which prevents p65 translocation and reducing inflammation \[[@CR12], [@CR13]\].Table 1Alveolar cellular effects of hypercapnia: summary of in vivo and ex vivo experiments on the effects of hypercapniaStudyExperimental modelApplied CO~2~Cellular effectsBroccard et al. \[[@CR4]\]VILI ex vivo (rabbit)PaCO~2~ target 70--100 mmHgHCA reduced microvascular permeability, lung edema formation, and BAL protein contentYang et al. \[[@CR20]\]VILI in vivo (rat) and in vitro alveolar epithelial cellsPaCO~2~ target 80--100 mmHgHCA attenuated microvascular leak, oxidative stress, and inflammationDoerr et al. \[[@CR65]\]VILI/plasma wound resealing. Ex vivo (rat) and in vitro alveolar epithelial cell12%Hypercapnia reduced plasma membrane resealing in vivo and in vitroO'Toole et al. \[[@CR8]\]In vitro three cell respiratory lines10, 15%Hypercapnia reduced rate of wound closure (cell migration) via NF-κB pathway inhibitionO'Croinin et al. \[[@CR17]\]*E. coli* pneumonia (48 h). In vivo (rat)8%Hypercapnia worsened lung injury induced by prolonged untreated *E. coli* pneumoniaWang et al. \[[@CR21]\]Endotoxin stimulation. In vitro human and mouse macrophages5, 9, 12.5, 20%Hypercapnia inhibited macrophage phagocytosis*HCA* hypercapnic acidosis, *VILI* ventilator-induced lung injury, *BAL* bronchoalveolar lavage, *NF-[k]{.smallcaps}B* nuclear factor kappa B

It also attenuated apoptosis in rabbits subjected to ischemia and reperfusion injury \[[@CR6]\], and buffering hypercapnic acidosis worsened lung injury in this model \[[@CR14]\]. One of the proposed mechanisms is the inhibitory action of CO~2~ on the ADAM-17 (a sheddase), thus preventing the activation of the p44/p42 MAPK pathway and, by this way, reducing apoptosis \[[@CR15]\]. Finally, hypercapnia resulted in less cell injury and neutrophil adherence to endothelial monolayers in stimulated pulmonary endothelial cells \[[@CR16]\].

Contrasting, in rats exposed to hypercapnia for 48 h, a challenge with *Escherichia coli* caused neutrophils to have impaired phagocytic activity, with higher bacterial colony counts in the lungs of these animals, possibly because of impairment in neutrophil function under sustained hypercapnic acidotic environment \[[@CR17]\]. Hypercapnia worsened injury and induce apoptosis in alveolar type 2 epithelial cells via a nitric oxide-dependent pathway in an in vitro model with fetal rat alveolar cells pre-incubated with lipopolysaccharide (LPS) and cytokines \[[@CR18]\]. Also, hypercapnia dose-dependently impaired alveolar cell proliferation and delayed wound repair in an in vitro scratch wound model of three different types of human lung cells \[[@CR8]\]. These effects persisted with buffering of the hypercapnic acidosis. In line with this observation, in ex vivo and in vitro rat models of ventilator-induced lung injury (VILI), hypercapnic acidosis impaired membrane wound resealing. Carbon dioxide rather than pH reduced the rate of wound closure (cell migration) in a dose-dependent manner via NF-[k]{.smallcaps}B pathway inhibition. Furthermore, hypercapnia caused mitochondrial dysfunction and impaired cell proliferation in an in vitro model of cultured human alveolar epithelial cells by induction of miR-183, a microRNA, which in turn downregulated isocitrate dehydrogenase 2, a key enzyme of the tricarboxylic acid cycle that catalyzes the conversion of isocitrate to α-ketoglutarate, leading to mitochondrial dysfunction and impaired proliferation of alveolar epithelial cells \[[@CR19]\].

Effects of hypercapnia on humoral processes (Table [2](#Tab2){ref-type="table"}) {#Sec4}
--------------------------------------------------------------------------------

Hypercapnia has been found to attenuate cytokine production and oxygen free radical formation in mice subjected to alveolar stretch \[[@CR5], [@CR15]\]. Furthermore, hypercapnia markedly reduced apoptosis, oxidative stress, and inflammation in alveolar epithelial cells from high-pressure ventilation-stimulated rat lungs \[[@CR20]\]. Hypercapnic acidosis (HCA) exerts anti-inflammatory effects in rabbits with endotoxin-induced lung injury \[[@CR16]\].Table 2Humoral effects of hypercapnia: summary of in vivo and ex vivo experiments on the effects of hypercapniaStudyExperimental modelApplied CO~2~Humoral effectsShibata et al. \[[@CR7]\]Free-radical ex vivo (rabbit)25%HCA attenuated free-radical injury via inhibition of endogenous xanthine oxidaseLaffey et al. \[[@CR6]\]Pulmonary IR ex vivo (rabbit)12%HCA reduced TNF-α, 8-isoprostane, nitrotyrosine generation in the lung tissue and reduced apoptosisYang et al. \[[@CR20]\]VILI in vivo (rat) and in vitro alveolar epithelial cellsPaCO~2~ target 80--100 mmHgHCA reduced caspase-3 activation (apoptosis), MPO, MDA, via ASK-1-JNK/p38 pathway inhibitionOtulakowski et al. \[[@CR15]\]VILI ex vivo (mouse) and in vitro alveolar epithelial cells12%Hypercapnia prevented activation of EGFR and p44/42 MAPK pathway in vitro. TNFR shedding (on ADAM-17 ligand induced by stretch injury) was reduced in vivoTakeshita et al. \[[@CR16]\]Endotoxin in vitro pulmonary endothelial cells10%Hypercapnia reduced cell injury and prevented IκB degradation. NF-κB-dependent cytokine production was reducedO'Toole et al. \[[@CR8]\]In vitro three cell respiratory lines10, 15%Hypercapnia inhibited p65 translocation and IκB degradationCummins et al. \[[@CR13]\]Endotoxin stimulated. In vitro six different cell lines5, 10%CO~2~ reduced the expression of innate immune effectors IL-6 and TNF-αWang et al. \[[@CR21]\]Endotoxin stimulation. In vitro human and mouse macrophages5, 9, 12.5, 20%Hypercapnia reduced cytokine release (IL-6, TNF-α)*HCA* hypercapnic acidosis, *ADAM-17* ADAM metallopeptidase 17, *ASK-1* apoptosis signal-regulating kinase-1, *EGRF* epidermal growth factor receptor, *IkB* inhibitory kappa B, *IL-6* interleukin-6, *IR* ischemia-reperfusion, *JNK* c-Jun N-terminal kinase, *MDA* malondialdehyde, *MPO* myeloperoxidase, *NF-kB* nuclear factor kappa B, *p44/42 MAPK* p44/p42 mitogen-activated protein kinase, *TNF-α* tumor necrosis factor-α, *TNFR* tumor necrosis factor receptor, *VILI* ventilator-induced lung injury

On the contrary, hypercapnia has been found to selectively inhibit the expressions of proinflammatory cytokines in human and mouse macrophage cell lines \[[@CR21]\]. In in vitro human cells' experiments, hypercapnia inhibited activation of the NF-κB pathway \[[@CR13], [@CR22]\], independent of pH.

Effects of hypercapnia on alveolar fluid clearance {#Sec5}
--------------------------------------------------

Hypercapnic acidosis reduced alveolar edema formation by inhibiting an increase in pulmonary capillary included by free radicals \[[@CR7]\], ischemia-reperfusion \[[@CR14]\], and high-stretch ventilation in in vitro and in vivo models \[[@CR23]\].

However, hypercapnia has also been found to decrease alveolar fluid clearance by decreasing Na^+^, K^+^-ATPase activity in the alveoli basal membrane in in vivo studies in large and small animal models \[[@CR9], [@CR24]\], in ex vivo studies using a rodent lung model \[[@CR10]\], and in human alveolar epithelial cells \[[@CR11]\].

Physiologic effects of hypercapnia---animal and human studies {#Sec6}
=============================================================

Several studies have shown various effects of hypercapnia on the respiratory system.

Effects of hypercapnia on airway resistance {#Sec7}
-------------------------------------------

Hypercapnia may either decrease or increase airway resistance. Alveolar hypercapnia decreases airway resistance by relaxing smooth muscle small bronchi (a direct effect) in healthy subjects \[[@CR25]\], while systemic hypercapnia causes vagal nerve-mediated constriction of the larger airway (an indirect effect) in animal models \[[@CR26]\]. These opposing but balanced effects may produce a little net alteration in airway resistance \[[@CR27]\].

Effects of hypercapnia on the oxygenating capacity of the lung {#Sec8}
--------------------------------------------------------------

Hypercapnia potentiates hypoxic pulmonary vasoconstriction with a reduction in intrapulmonary shunt, improving gas exchange in normal \[[@CR28]--[@CR30]\] and diseased lungs \[[@CR31], [@CR32]\]. Hypercapnia also increases lung compliance, directing ventilation to the underventilated lung regions resulting in a better match between ventilation and perfusion in the lung of dogs \[[@CR33]\]. The mechanism might be through increased alveolar surfactant secretion and more effective surface tension-lowering properties of surfactant under acidic conditions \[[@CR31]\]. However, in an in vivo rat model of prolonged *E. coli* pneumonia, hypercapnia lowered static lung compliance compared to normocapnia \[[@CR17]\]. Sustained hypercapnia may impair neutrophil function, increasing bacterial load, contributing to increased lung injury and worst compliance \[[@CR14]\].

Both hypercapnia and hypercapnic acidosis shift the hemoglobin--oxygen dissociation curve to the right and may increase hematocrit, augmenting the release of oxygen to the tissues in a canine model \[[@CR34]\]. It also increases cardiac output through sympathoadrenal mechanisms \[[@CR35]\]. The secondary rise in cardiac output is associated with increased preload, afterload, contractility, and elevated heart rate \[[@CR36]\]. The overall effect is better oxygenation and improved global oxygen supply.

On the other hand, hypercapnia lowers alveolar oxygen tension by the following formula P~A~O~2~ = FiO~2~ (*P*~*B*~-47)---(PaCO~2~/*R*), where P~A~O~2~ is the alveolar oxygen tension, *P*~*B*~ is the barometric pressure, and *R* is the respiratory quotient. However, compared to alterations in FiO~2~ \[[@CR37]\], the effect on alveolar oxygenation by alterations in alveolar ventilation is small.

The overall effect of these mechanisms is that blood oxygenation may remain mostly unchanged or improved.

Effects of hypercapnia on diaphragm function {#Sec9}
--------------------------------------------

Hypercapnic acidosis preserves diaphragmatic contractility and prevents ventilation-induced diaphragmatic myosin loss and inflammation in pigs \[[@CR38]\]. However, hypercapnic acidosis impairs diaphragmatic function in spontaneously breathing patients, through effects on afferent transmission by the vagal nerve \[[@CR39]\].

The clinical effect of hypercapnia upon diaphragmatic function needs to be further elucidated.

Effects of hypercapnia on pulmonary vasculature {#Sec10}
-----------------------------------------------

In models of pulmonary hypertension induced by chronic hypoxia and right ventricular dysfunction, hypercapnic acidosis attenuates pulmonary hypertension, normalizes right ventricular function, and preserves the endothelial integrity and pulmonary vascular remodeling \[[@CR40]--[@CR42]\]. The effects of hypercapnic acidosis on vasoconstriction and resistance in the pulmonary circulation have also been found in humans \[[@CR35]\]. These effects are exacerbated in the setting of preexisting pulmonary hypertension, such as found with ARDS \[[@CR43]\].

The impact of hypercapnia in acute respiratory distress syndrome {#Sec11}
================================================================

Supportive care with mechanical ventilation remains the mainstay of ARDS management with a goal to minimize lung injury caused by the forces created by mechanical ventilation. Treatment algorithms for ARDS typically begin with optimization of the settings to achieve the so-called lung-protective ventilation and proceed through increasing invasiveness based on physiological goals of gas exchange. These include higher positive end-expiratory pressures, lung recruitment manoeuvers, prone positioning, and extracorporeal removal of carbon dioxide.

Permissive hypercapnia {#Sec12}
----------------------

Lung-protective ventilation with volumes limited to 6--8 mL/kg of predicted body weight (PBW) or lower, and plateau pressure \< 30 cm H~2~O, dramatically increases survival \[[@CR2]\]. As a consequence of reducing alveolar ventilation with lower tidal volumes, hypercapnia results. Recognizing that low tidal volume ventilation confers survival benefits by reducing lung stretch and the cyclical collapse of alveoli, clinicians have accepted hypercapnia, giving rise to the concept of permissive hypercapnia \[[@CR44]\]. However, it remains unclear whether hypercapnic acidosis carries survival benefits independent of using low tidal volumes (Table [3](#Tab3){ref-type="table"}).Table 3Randomized controlled studies in lung-protective ventilation and PaCO~2~ levelsStudyMortality benefitPaCO~2~ in control arm (mmHg ± SD)PaCO~2~ in LPV arm (mmHg ± SD)Buffer usedARDSNet \[[@CR2]\]Yes35.8 ± 8.040.0 ± 10.0YesAmato et al. \[[@CR66]\]Yes36.0 ± 1.558.0 ± 3.0NoBrochard et al. \[[@CR46]\]No41.0 ± 7.559.5 ± 19.0NoBrower et al. \[[@CR67]\]No40.1 ± 1.650.3 ± 3.5YesStewart et al. \[[@CR68]\]No46.1 ± 1054.5 ± 15No*LPV* lung-protective ventilation

In a retrospective analysis of the ARDS network, hypercapnic acidosis was associated with lower mortality in the group of patients receiving tidal volumes of 12 mL/kg PBW. However, there was no survival benefit in patients ventilated at tidal volumes of 6 mL/kg PBW \[[@CR45]\]. It was hypothesized that lung-protective ventilation reduced lung injury caused by the ventilator to a point where the protective effect of hypercapnic acidosis could not be detected.

In a multicenter randomized clinical trial comparing low (7 mL/kg PBW) with conventional tidal volumes (10 mL/kg PBW), a trend towards higher mortality was observed in patients who developed hypercapnia and acidosis \[[@CR46]\]. These findings resulted in a premature stop of that trial, making interpretation of the results difficult.

Recently, a post hoc analysis of three prospective non-interventional international studies in ARDS patients was published \[[@CR47]\]. In this analysis, severe hypercapnia (PaCO~2~ \> 50 mmHg) was associated with higher mortality and more organ failures compared to patients with normocapnia. Acidosis or the combination of hypercapnia and acidosis independently increased the risk of mortality in the intensive care unit. The incidence of severe hypercapnia increased significantly with the time (1998, 2004, and 2010) as a consequence of the diverse respiratory strategies practiced over the years, which may reflect the feeling of many intensivists that hypercapnia could be beneficial \[[@CR47]\].

Finally, one retrospective analysis including over 250,000 ARDS patients receiving mechanical ventilation showed that patients who developed hypercapnic acidosis (pH \< 7.35 PaCO~2~ \> 65 mmHg) during the first 24 h of mechanical ventilation had significantly higher mortality than those who had compensated hypercapnia or normocapnia \[[@CR48]\].

Lung overdistension {#Sec13}
-------------------

The rationale for using positive end-expiratory pressure (PEEP) is to mitigate the injurious effects of repetitive opening and closing of lung units by restoring the functional size of the lung, promoting lung protection, and improving gas exchange and lung mechanics. However, high levels of PEEP may lead to overdistension of lung units, especially those that remained normally aerated within heterogeneous ARDS lungs, and this may increase alveolar dead space \[[@CR49]--[@CR51]\]. The consequence of this will be a rise of carbon dioxide levels.

In a recent international randomized clinical trial in ARDS patients, the use of the "open lung approach" actually increased 28-day mortality \[[@CR52]\]. Notably, this trial used aggressive recruitment manoeuvers and "super high" levels of positive end-expiratory pressure compared to previous trials \[[@CR53]--[@CR55]\]. It is also worth to note that patients in this trial had much higher blood carbon dioxide levels than patients in previous trials that tested the "open lung approach." It could be hypothesized that this reflects an increase in dead space secondary to overdistension.

Extracorporeal CO~2~ removal (Table [4](#Tab4){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}) {#Sec14}
====================================================================================================================

Despite lung-protective ventilation strategies, up to 30% of patients with ARDS have evidence of tidal hyperinflation, representing a potential risk of VILI \[[@CR56]\]. A strategy of "ultraprotective ventilation" with tidal volumes lower than 6 mL/kg PBW requires extracorporeal decapneization.Table 4Relevant clinical studies of ECCO~2~R in ARDS patientsStudyECCO~2~R techniqueDescription and resultsTerragni et al. \[[@CR56]\]Modified continuous VV hemofiltration system with membrane lung via a 14-Fr single dual lumen catheter (femoral) with an extracorporeal blood flow of 191--422 mL/minProspective study.Ten ARDS patients with 28 ≤ Pplat ≤ 30 after 72 h of ARDSNet ventilation were placed on ECCO~2~R and had a progressive reduction in V~T.~V~T~ was reduced from 6.3 ± 0.2 to 4.2 ± 0.3 mL/kg PBW and Pplat decreased from 29.1 ± 1.2 to 25.0 ± 1.2 cmH~2~O (*P* \< 0.001).Consequent respiratory acidosis was managed by ECCO~2~R.Improvement of morphological markers of lung protection and reduction in pulmonary cytokines (*P* \< 0.01) after 72 h of ventilation with *V*T \< 6 mL/kg PBW.No patient-related complications.Membrane clotting in three patients.Bein et al. \[[@CR58]\]Femoral AV pumpless extracorporeal lung assist (PECLA) via a 15-Fr arterial cannula and 17-Fr venous cannula with a mean extracorporeal blood flow of 1.3 L/minRandomized controlled trial.Moderate/severe ARDS after 24-h stabilization period with higher PEEP.Randomized to ECCO~2~R group with \~ 3 mL/kg PBW ventilation or control group with \~ 6 mL/kg PBW ventilation.There were no significant differences in VFDs at day 28 (10 vs. 9 days, *P* = 0.78) or day 60 (33 vs. 29, *P* = 0.47).Post hoc analysis showed that patients with P/F ≤ 150 at randomization in ECCO~2~R group had a significantly shorter duration of ventilation (VFDs at day 60, 41 vs. 28, *P* = 0.033).Significantly higher red blood cell transfusion in the PECLA group up to day 10 (3.7 vs. 1.5 units, *P* \< 0.05).Fanelli et al. \[[@CR59]\]VV configuration via a 15.5-Fr single dual lumen catheter (femoral or jugular) with a mean extracorporeal blood flow of 435 mL/minProspective study.Moderate/severe ARDS.V~T~ was reduced from baseline to 4 mL/kg PBW.Low-flow ECCO~2~R was initiated when pH \< 7.25 and PaCO~2~ \> 60 mmHg.ECCO~2~R was effective in correcting pH and PaCO~2~.Life-threatening hypoxemia such as prone position and ECMO were necessary in four and two patients, respectively.Schmidt et al. \[[@CR69]\]VV configuration managed with renal replacement platform via a 15.5-Fr single dual lumen catheter (femoral or jugular) with a mean extracorporeal blood flow of 421 mL/minProspective multicenter study.Twenty-two patients with mild/moderate ARDSV~T~ gradually reduced following 2-h run-in time from 6 to 5, 4.5, and 4 mL/kg every 30 min and PEEP adjusted to reach 23 ≤ P~plat~ ≤ 25 cmH~2~O.No patients required ECMO.No worsening oxygenation.Low-flow ECCO~2~R managed by RRT platform easily and safely enabled ultraprotective ventilation.Performance of RRT ECCO~2~R in severe ARDS patients not known.Combes et al. (NCT 02282657) \[[@CR70]\]VV configuration 15.5 to 19 Fr single dual lumen catheter (femoral or jugular) with three different devices.Prospective multicenter study.Ninety-five patients with moderate ARDS. V~T~ progressively decreased to 4 mL/kg PBW.PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cmH~2~O.Objective to maintain PaCO~2~ ± 20% of baseline values obtained at V~T~ 6 mL/kg IBW with pH \> 7.30.ECCO~2~R was able to reduce Pplat from 26 ± 5 cmH~2~O to 23 ± 3 cmH~2~O (*P* \< 0.01) in 73% of patients.ECCO~2~R was able to increase PEEP from 12 ± 4 cmH~2~O to 14 ± 4 cmH~2~O (*P* \< 0.01).ECCO~2~R allowed ∆P reduction from 13 ± 5 to 9 ± 4 cmH~2~O (*P* \< 0.01).There were no significant changes in pH, PaCO~2~, and PaO~2~/FiO~2~ with V~T~ reduction to 4 mL/kg/IBWECCO~2~R device length: 5 (3--8 days).Derecruitment/hypoxia (*n* = 2) that need to increase V~T~, hemolysis (*n* = 3). Hemorrhage at the cannula insertion point (*n* = 4), pneumothorax (*n* = 1).

This approach has been tested in two trials in ARDS patients, resulting in less lung injury caused by ventilation \[[@CR57]\] and a decrease in the number of ventilation days \[[@CR58]\]. In one feasibility study, ECCO~2~R facilitated ventilation with ultralow tidal volumes near to 3 mL/kg PBW, while preventing hypercapnic acidosis \[[@CR59]\]. These findings were confirmed in a recently completed international multicenter randomized clinical trial ([ClinicalTrials.gov/ct2/show/NCT02282657](http://clinicaltrials.gov/ct2/show/NCT02282657)). One currently recruiting randomized clinical trial evaluates whether ultraprotective ventilation by employing ECCO~2~R affects 90-day mortality in patients with hypoxemic acute respiratory failure ([ClinicalTrials.gov/ct2/show/NCT02654327](http://clinicaltrials.gov/ct2/show/NCT02654327)).

Although ECCO~2~R seems to be effective in mitigating hypercapnic acidosis and possibly in reducing VILI and mechanical ventilation days, ECCO~2~R may have pulmonary and hemodynamic consequences. It can be associated to adverse effects such worsening hypoxemia and increased FiO~2~ requirements due to a decrease in mean airway pressure, low ventilation-perfusion ratio, and lower partial pressure of alveolar oxygen secondary to a decreased lung respiratory quotient \[[@CR60], [@CR61]\]. Besides, because of the low flow system of ECCO~2~R, higher anticoagulation requirements are needed in order to maintain ECCO~2~R efficiency and performance. Therefore, significant complications may occur as a consequence of anticoagulation or catheter insertion with hemodynamic instability and a higher number of red blood cell transfusions needed \[[@CR59], [@CR62]--[@CR64]\].

It is worth to say that ECCO~2~R may be a promising adjuvant therapeutic strategy for reducing the impact of mechanical ventilation through ultraprotective ventilation rather than to mitigate hypercapnia in patients under conventional lung-protective ventilation. For the time being, the available literature does not provide definitive information on the usefulness of ECCO~2~R in patients with acute respiratory failure. Its use for the moment is experimental.

Conclusion {#Sec15}
==========

It is increasingly recognized that CO~2~ is much more than just a waste product of cellular metabolism. Indeed, it should be seen as a potent biological agent that exerts protective as well as harmful effects. Hypercapnia may develop in ARDS patients, and what the exact impact of high carbon dioxide levels on the outcome remains uncertain. More importantly, whether it should be accepted or whether it should be prevented or treated with invasive techniques for extracorporeal removal remains highly uncertain.

Additional file
===============

 {#Sec16}

Additional file 1:**Table S1.** Ongoing studies of ECCO~2~R in ARDS. (DOCX 16 kb)

ARDS

:   Acute respiratory distress syndrome

CO~2~

:   Carbon dioxide

ECCO~2~R

:   Extracorporeal carbon dioxide removal

HCA

:   Hypercapnic acidosis

LPS

:   Lipopolysaccharide

NF-[k]{.smallcaps}B

:   Nuclear factor kappa B

PaCO~2~

:   Partial arterial pressure of carbon dioxide

PaO~2~

:   Partial alveolar pressure of oxygen

PBW

:   Predicted body weight

VILI

:   Ventilator-induced lung injury
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